middle.news
Neuren’s DAYBUE Sales Climb 11% as European Launch Nears
9:02am on Thursday 8th of May, 2025 AEST
•
Pharmaceuticals
Read Story
Neuren’s DAYBUE Sales Climb 11% as European Launch Nears
9:02am on Thursday 8th of May, 2025 AEST
Key Points
Q1 2025 DAYBUE US net sales up 11% to US$84.6 million
Neuren’s Q1 2025 royalty income rises 17% to A$13.5 million
Record 954 unique patients treated, with improved persistency rates
Full-year 2025 US sales guidance maintained at US$380–405 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE